Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Update

Posted by Shane Hupp on Feb 3rd, 2026

Jyong Biotech Ltd. (NASDAQ:MENS – Get Free Report) was the recipient of a large decline in short interest in January. As of January 15th, there was short interest totaling 525,468 shares, a decline of 19.0% from the December 31st total of 649,057 shares. Approximately 0.7% of the company’s stock are short sold. Based on an average trading volume of 374,723 shares, the short-interest ratio is currently 1.4 days. Based on an average trading volume of 374,723 shares, the short-interest ratio is currently 1.4 days. Approximately 0.7% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jyong Biotech in a report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Check Out Our Latest Report on MENS

Institutional Investors Weigh In On Jyong Biotech

Institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets bought a new stake in Jyong Biotech in the third quarter valued at about $67,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Jyong Biotech in the 4th quarter valued at approximately $49,000. Finally, Millennium Management LLC acquired a new stake in shares of Jyong Biotech during the 3rd quarter valued at approximately $512,000.

Jyong Biotech Stock Performance

Shares of Jyong Biotech stock traded up $0.04 on Monday, hitting $2.40. 293,945 shares of the company’s stock traded hands, compared to its average volume of 373,094. Jyong Biotech has a 52-week low of $2.30 and a 52-week high of $67.00. The firm’s 50-day moving average is $11.05 and its 200 day moving average is $32.47.

Jyong Biotech Company Profile

(Get Free Report)

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.